# Izumi Ohno

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/izumi-ohno/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,596 |
| Field | Pancreatic and Hepatic Oncology Research |
| h-index | 24 |
| i10-index | 56 |
| Last Known Institution | Chiba University |
| OpenAlex ID | https://openalex.org/A5064282637 |
| ORCID iD | 0000-0001-6434-6797 |
| Works | 263 |

## Researcher papers

- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study](https://scholariq.org/papers/nivolumab-alone-or-in-combination-with-cisplatin-plus-gemcitabine-in-japanese/)
- [Anodic Oxidation of Reductants in Electroless Plating](https://scholariq.org/papers/anodic-oxidation-of-reductants-in-electroless-plating/)
- [Electrochemistry of electroless plating](https://scholariq.org/papers/electrochemistry-of-electroless-plating/)
- [Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer](https://scholariq.org/papers/serum-levels-of-il-6-and-il-1-can-predict-the-efficacy-of-gemcitabine-in/)
- [NADPH Oxidase Promotes Pancreatic Cancer Cell Survival via Inhibiting JAK2 Dephosphorylation by Tyrosine Phosphatases](https://scholariq.org/papers/nadph-oxidase-promotes-pancreatic-cancer-cell-survival-via-inhibiting-jak2/)
- [Ellagic acid induces apoptosis through inhibition of nuclear factor kB in pancreatic cancer cells](https://scholariq.org/papers/ellagic-acid-induces-apoptosis-through-inhibition-of-nuclear-factor-kb-in/)
- [REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.](https://scholariq.org/papers/reach-2-a-randomized-double-blind-placebo-controlled-phase-3-study-of/)
- [Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels](https://scholariq.org/papers/characterization-of-patients-with-advanced-pancreatic-cancer-and-high-serum/)
- [First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors](https://scholariq.org/papers/first-in-human-phase-i-study-of-an-oral-hsp90-inhibitor-tas-116-in-patients-with/)
- [Outcomes and Post-removal Course of Lumen-Apposing Metal Stent Placement for Peripancreatic Fluid Collections: A Comparative Study of Pancreatic Pseudocysts and Walled-Off Necrosis](https://scholariq.org/papers/outcomes-and-post-removal-course-of-lumen-apposing-metal-stent-placement-for/)

## Researcher topics

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Electrodeposition and Electroless Coatings](https://scholariq.org/topics/electrodeposition-and-electroless-coatings/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Researcher university

- [Chiba University](https://scholariq.org/institutions/chiba-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.